Managers / Q3 2022 · view latest →
Decheng Capital Management III (Cayman), LLC
CIK 0001747821 · PO BOX 309, UGLAND HOUSE, GRAND CAYMAN, E9, KY1-1104 · 345-949-8066
Summary
Decheng Capital Management III (Cayman), LLC reported $276M in U.S.-listed holdings across 26 positions for Q3 2022.
Its largest position, NVLSEUR, represents 17.5% of the portfolio.
Compared with Q2 2022, the fund opened 3 new positions and exited 2.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 73.2% · $202M
- Other · 26.8% · $74M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| Apexigen, Inc. | NEW | +1.89M | 1.89M | +$5M | $5M |
| SGENUSDSeagen Inc. | NEW | +23.0K | 23.0K | +$3M | $3M |
| Argenx SE | NEW | +5.5K | 5.5K | +$2M | $2M |
| MASS908 Devices Inc. | SOLD OUT | −20.0K | 0 | −$412,000 | $0 |
| Singular Genomics Systems, Inc. | SOLD OUT | −20.0K | 0 | −$76,000 | $0 |
| NVLSEURAlpine Immune Sciences, Inc. | ADDED | +2.00M | 6.71M | +$8M | $48M |
| Horizon Therapeutics PLC | ADDED | +23.5K | 78.9K | +$464,000 | $5M |
| BDQMAlbireo Pharma, Inc. | ADDED | +105.0K | 623.3K | +$2M | $12M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2022
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q4 2023 | $300M | 26 | Dec 12, 2023 | RESTATEMENT | changes · EDGAR ↗ |
| Q3 2023 | $313M | 27 | Nov 29, 2023 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2023 | $319M | 25 | Jul 28, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $248M | 24 | May 10, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $267M | 26 | Feb 9, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $276M | 26 | Nov 8, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $264M | 25 | Aug 1, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $326M | 24 | May 10, 2022 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.